Effect of ramelteon on sleep disturnace and reflux symptoms in patients with gastroesophagealreflux disease

Effect of ramelteon on sleep disturnace and reflux symptoms in patients with gastroesophagealreflux disease - Ramelteon and GERD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008500

Enrollment

Registered

2012-09-01

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD

Interventions

Ramelteon 8mg, 12 week administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. GERD patients with insomina (difficulty in falling asleep) 2. Outpatients

Exclusion criteria

Exclusion criteria: 1. Allergy of ramelteon 2. Severe liver dysfunction 3. Allergy of fluvoxamine maleate 4. Other hyptonic drugs use 5. Nightworker, shift worker

Design outcomes

Primary

Measure	Time frame
Improvement in FSSG scores	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026